$heff's $tation of $tocks & $olid DD

[Trade_zecco]

ALTH ($4.61)- phase II study of Folotyn versus Tarceva in non-small cell lung cancer on October 11.

Allos Therapeutics(ALTH_)

Drug: Folotyn

Indication: Non-small cell lung cancer

Presentation: Mon. Oct. 11

Full presentation of data from a phase II study of Folotyn versus Tarceva in non-small cell lung cancer. In July, Allos said preliminary results from the study demonstrated that Folotyn reduced the risk of death compared to Tarceva, although the results were not statistically significant. In patients with non-squamous cell lung cancer, which comprises the largest subgroup of lung cancer patients, Folotyn demonstrated a 35% reduction in the risk of death compared to Tarceva. This subgroup is important because it's where Astellas (formerly OSI Pharmaceuticals) generated the bulk of Tarceva's $1.2 billion in 2009 worldwide sales.